S&P 500   3,894.70 (+2.19%)
DOW   31,589.17 (+2.12%)
QQQ   321.81 (+2.44%)
AAPL   125.94 (+3.86%)
MSFT   236.38 (+1.72%)
FB   261.43 (+1.48%)
GOOGL   2,059.08 (+1.84%)
TSLA   716.61 (+6.09%)
AMZN   3,123.16 (+0.98%)
NVDA   548.21 (-0.07%)
BABA   239.59 (+0.77%)
CGC   35.21 (+7.51%)
GE   13.22 (+5.42%)
MU   94.25 (+2.97%)
NIO   49.70 (+8.56%)
AMD   85.45 (+1.11%)
T   28.28 (+1.40%)
F   12.01 (+2.65%)
ACB   11.36 (+7.98%)
DIS   195.96 (+3.66%)
BA   225.66 (+6.44%)
NFLX   551.50 (+2.35%)
BAC   35.70 (+2.85%)
S&P 500   3,894.70 (+2.19%)
DOW   31,589.17 (+2.12%)
QQQ   321.81 (+2.44%)
AAPL   125.94 (+3.86%)
MSFT   236.38 (+1.72%)
FB   261.43 (+1.48%)
GOOGL   2,059.08 (+1.84%)
TSLA   716.61 (+6.09%)
AMZN   3,123.16 (+0.98%)
NVDA   548.21 (-0.07%)
BABA   239.59 (+0.77%)
CGC   35.21 (+7.51%)
GE   13.22 (+5.42%)
MU   94.25 (+2.97%)
NIO   49.70 (+8.56%)
AMD   85.45 (+1.11%)
T   28.28 (+1.40%)
F   12.01 (+2.65%)
ACB   11.36 (+7.98%)
DIS   195.96 (+3.66%)
BA   225.66 (+6.44%)
NFLX   551.50 (+2.35%)
BAC   35.70 (+2.85%)
S&P 500   3,894.70 (+2.19%)
DOW   31,589.17 (+2.12%)
QQQ   321.81 (+2.44%)
AAPL   125.94 (+3.86%)
MSFT   236.38 (+1.72%)
FB   261.43 (+1.48%)
GOOGL   2,059.08 (+1.84%)
TSLA   716.61 (+6.09%)
AMZN   3,123.16 (+0.98%)
NVDA   548.21 (-0.07%)
BABA   239.59 (+0.77%)
CGC   35.21 (+7.51%)
GE   13.22 (+5.42%)
MU   94.25 (+2.97%)
NIO   49.70 (+8.56%)
AMD   85.45 (+1.11%)
T   28.28 (+1.40%)
F   12.01 (+2.65%)
ACB   11.36 (+7.98%)
DIS   195.96 (+3.66%)
BA   225.66 (+6.44%)
NFLX   551.50 (+2.35%)
BAC   35.70 (+2.85%)
S&P 500   3,894.70 (+2.19%)
DOW   31,589.17 (+2.12%)
QQQ   321.81 (+2.44%)
AAPL   125.94 (+3.86%)
MSFT   236.38 (+1.72%)
FB   261.43 (+1.48%)
GOOGL   2,059.08 (+1.84%)
TSLA   716.61 (+6.09%)
AMZN   3,123.16 (+0.98%)
NVDA   548.21 (-0.07%)
BABA   239.59 (+0.77%)
CGC   35.21 (+7.51%)
GE   13.22 (+5.42%)
MU   94.25 (+2.97%)
NIO   49.70 (+8.56%)
AMD   85.45 (+1.11%)
T   28.28 (+1.40%)
F   12.01 (+2.65%)
ACB   11.36 (+7.98%)
DIS   195.96 (+3.66%)
BA   225.66 (+6.44%)
NFLX   551.50 (+2.35%)
BAC   35.70 (+2.85%)
Log in
NASDAQ:OPTN

OptiNose Stock Forecast, Price & News

$3.97
+0.09 (+2.32 %)
(As of 03/1/2021 11:12 AM ET)
Add
Compare
Today's Range
$3.93
Now: $3.97
$4.04
50-Day Range
$3.98
MA: $4.29
$4.75
52-Week Range
$3.14
Now: $3.97
$10.00
Volume6,699 shs
Average Volume433,939 shs
Market Capitalization$206.76 million
P/E RatioN/A
Dividend YieldN/A
Beta1.03
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps. It is also developing XHANCE, which is in Phase IIIb clinical trial for the treatment of chronic sinusitis; and OPN-300 for the treatment of Prader-Willi syndrome, a rare genetic obesity disorder, as well as autism spectrum disorder. The company has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail (sumatriptan nasal powder) to treat migraine in adults; and Inexia Limited to develop, manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. OptiNose, Inc. was founded in 2010 and is headquartered in Yardley, Pennsylvania.
OptiNose logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:OPTN
CUSIPN/A
Phone267-364-3500
Employees221
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$34.63 million
Book Value$1.48 per share

Profitability

Net Income$-110,050,000.00
Net Margins-230.14%

Miscellaneous

Market Cap$206.76 million
Next Earnings Date3/3/2021 (Confirmed)
OptionableNot Optionable

MarketRank

Overall MarketRank

1.61 out of 5 stars

Medical Sector

331st out of 1,962 stocks

Pharmaceutical Preparations Industry

162nd out of 772 stocks

Analyst Opinion: 3.3Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
$3.97
+0.09 (+2.32 %)
(As of 03/1/2021 11:12 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive OPTN News and Ratings via Email

Sign-up to receive the latest news and ratings for OPTN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











OptiNose (NASDAQ:OPTN) Frequently Asked Questions

Is OptiNose a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OptiNose in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" OptiNose stock.
View analyst ratings for OptiNose
or view top-rated stocks.

What stocks does MarketBeat like better than OptiNose?

Wall Street analysts have given OptiNose a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but OptiNose wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting OptiNose?

OptiNose saw a increase in short interest during the month of February. As of February 12th, there was short interest totaling 4,720,000 shares, an increase of 33.3% from the January 28th total of 3,540,000 shares. Based on an average daily trading volume, of 477,400 shares, the days-to-cover ratio is currently 9.9 days. Approximately 16.3% of the shares of the stock are sold short.
View OptiNose's Short Interest
.

When is OptiNose's next earnings date?

OptiNose is scheduled to release its next quarterly earnings announcement on Wednesday, March 3rd 2021.
View our earnings forecast for OptiNose
.

How can I listen to OptiNose's earnings call?

OptiNose will be holding an earnings conference call on Wednesday, March 3rd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were OptiNose's earnings last quarter?

OptiNose, Inc. (NASDAQ:OPTN) announced its quarterly earnings data on Thursday, November, 5th. The company reported ($0.43) EPS for the quarter, topping the Zacks' consensus estimate of ($0.56) by $0.13. The firm earned $15.44 million during the quarter, compared to analysts' expectations of $15.40 million. OptiNose had a negative net margin of 230.14% and a negative trailing twelve-month return on equity of 294.64%.
View OptiNose's earnings history
.

How has OptiNose's stock been impacted by COVID-19?

OptiNose's stock was trading at $5.06 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, OPTN shares have decreased by 20.6% and is now trading at $4.02.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for OPTN?

3 equities research analysts have issued 12 month target prices for OptiNose's stock. Their forecasts range from $17.00 to $21.00. On average, they anticipate OptiNose's stock price to reach $19.00 in the next year. This suggests a possible upside of 372.6% from the stock's current price.
View analysts' price targets for OptiNose
or view top-rated stocks among Wall Street analysts.

Who are OptiNose's key executives?

OptiNose's management team includes the following people:
  • Mr. Peter K. Miller, CEO & Director (Age 60, Pay $1.02M)
  • Dr. Ramy A. Mahmoud M.D., M.P.H., Pres & COO (Age 56, Pay $743.72k)
  • Mr. Keith Alan Goldan, Chief Financial Officer (Age 50, Pay $603.73k)
  • Mr. Michael F. Marino, Chief Legal Officer & Corp. Sec. (Age 45, Pay $708.26k)
  • Mr. Jonathan Neely, VP of Investor Relations & Bus. Operations
  • Ms. Karen E. Brophy, VP of HR (Age 58)
  • Mr. John Messina, Sr. VP of Clinical Devel. & Medical Affairs
  • Mr. Victor M. Clavelli, Chief Commercial Officer (Age 48)
  • Ms. Helena Kyttari Djupesland, Co-Founder of Optinose AS (Norway) & Co-CEO of Optinose AS (Norway)

Who are some of OptiNose's key competitors?

What other stocks do shareholders of OptiNose own?

When did OptiNose IPO?

(OPTN) raised $101 million in an initial public offering (IPO) on Friday, October 13th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, Piper Jaffray, BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO.

What is OptiNose's stock symbol?

OptiNose trades on the NASDAQ under the ticker symbol "OPTN."

Who are OptiNose's major shareholders?

OptiNose's stock is owned by many different retail and institutional investors. Top institutional shareholders include Paradigm Capital Management Inc. NY (4.80%), BlackRock Inc. (4.50%), Tamarack Advisers LP (3.79%), Rice Hall James & Associates LLC (1.99%), Opaleye Management Inc. (0.84%) and Northern Trust Corp (0.74%). Company insiders that own OptiNose stock include Avista Capital Partners Ii Gp,, Joseph C Scodari, Keith A Goldan, Michael F Marino III, Peter K Miller, Ramy A Mahmoud and Thomas Edward Gibbs.
View institutional ownership trends for OptiNose
.

Which institutional investors are selling OptiNose stock?

OPTN stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Caas Capital Management LP, Walleye Capital LLC, Squarepoint Ops LLC, Rice Hall James & Associates LLC, Bank of New York Mellon Corp, Barclays PLC, and Alliancebernstein L.P.. Company insiders that have sold OptiNose company stock in the last year include Peter K Miller, and Ramy A Mahmoud.
View insider buying and selling activity for OptiNose
or view top insider-selling stocks.

Which institutional investors are buying OptiNose stock?

OPTN stock was bought by a variety of institutional investors in the last quarter, including Opaleye Management Inc., Paradigm Capital Management Inc. NY, JPMorgan Chase & Co., Tamarack Advisers LP, Virtu Financial LLC, Renaissance Technologies LLC, ExodusPoint Capital Management LP, and Nuveen Asset Management LLC. Company insiders that have bought OptiNose stock in the last two years include Joseph C Scodari, Keith A Goldan, and Michael F Marino III.
View insider buying and selling activity for OptiNose
or or view top insider-buying stocks.

How do I buy shares of OptiNose?

Shares of OPTN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is OptiNose's stock price today?

One share of OPTN stock can currently be purchased for approximately $4.02.

How much money does OptiNose make?

OptiNose has a market capitalization of $209.37 million and generates $34.63 million in revenue each year. The company earns $-110,050,000.00 in net income (profit) each year or ($2.63) on an earnings per share basis.

How many employees does OptiNose have?

OptiNose employs 221 workers across the globe.

What is OptiNose's official website?

The official website for OptiNose is www.optinose.com.

Where are OptiNose's headquarters?

OptiNose is headquartered at 1020 STONY HILL ROAD SUITE 300, YARDLEY PA, 19067.

How can I contact OptiNose?

OptiNose's mailing address is 1020 STONY HILL ROAD SUITE 300, YARDLEY PA, 19067. The company can be reached via phone at 267-364-3500 or via email at [email protected]


This page was last updated on 3/1/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.